INCYIncyte

1. Aug 31, 2026Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation.Other event · Form 8-K
2. Jul 28, 2026Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
3. Jul 6, 2026On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”)Other event · Form 8-K
4. Jun 22, 2026Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura ® (ruxolitinib) cream.Other event · Form 8-K
5. Jun 8, 2026On June 8, 2026, Incyte Corporation (the “Company”) issued a press release announcing it had entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC (“Vega Therapeutics”)Other event · Form 8-K
6. Apr 28, 2026Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
7. Mar 30, 2026On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026.Director or officer change · Form 8-K
8. Mar 26, 2026On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately.Director or officer change · Form 8-K
9. Mar 6, 2026On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics License Application (“sBLA”) for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung …Other event · Form 8-K
10. Feb 10, 2026Incyte Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
11. Dec 12, 2025Director Retirement On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.